FDMT 4D Molecular Therapeutics, Inc.
$14.47
4D Molecular Therapeutics, Inc. (FDMT) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $1.03 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +24.4% since its last earnings release on August 13, 2026.
4D Molecular Therapeutics Reported In-line with Estimates
Thursday, August 13, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($1.03)
Rev est $3.49M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$14.89
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About 4D Molecular Therapeutics, Inc.
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.